---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-027380"
form_type: "8-K"
ticker: "WINT"
cik: "0000946486"
company_name: "WINDTREE THERAPEUTICS INC /DE/"
filed_at: "2024-08-20T23:59:59+00:00"
generated_at: "2026-05-31T08:37:07.199827+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Windtree Q2 net loss $12M ($20.91/shr), istaroxime data expected Q3 2024

## Summary
- Net loss of $12.0M ($20.91 per share) on 0.6M shares; operating loss $11.5M vs. $6.8M in Q2 2023.
- R&D expense $9.9M (incl. $7.5M non-cash Varian asset acquisition cost) vs. $1.8M; G&A $1.6M vs. $2.4M.
- Cash $1.8M, current liabilities $8.8M; substantial doubt about going concern disclosed.
- Closed July transactions for $13.9M gross proceeds ($4.4M new funding, $9.5M note extinguishment); $35M equity line secured.
- Istaroxime Phase 2 SEISMiC study enrollment near complete, topline by end of Q3 2024; board added Saundra Pelletier, Jed Latkin.

## SEC filing metadata
- accession: 0001437749-24-027380
- form_type: 8-K
- ticker: WINT
- cik: 0000946486
- company_name: WINDTREE THERAPEUTICS INC /DE/
- filed_at: 2024-08-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/946486/000143774924027380/0001437749-24-027380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/946486/000143774924027380/wint20240529_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-027380
- JSON: https://secwatch.observer/filing/0001437749-24-027380.json
- Plain text: https://secwatch.observer/filing/0001437749-24-027380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.